


1954-363  
MC:smt



1617

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

APR 20 2001

TECH CENTER 1600/2900

In re Application of )  
Jerry L. NADLER et al. )  
Serial No. 09/739,843 ) Examiner: Unassigned  
Filed: December 20, 2000 ) Group Art Unit: 1617  
For: HUMAN LEUKOCYTE 12-LIPOXYGENASE AND ITS  
ROLE IN THE PATHOGENESIS OF DISEASE STATES

SECOND REQUEST FOR CORRECTION OF FILING RECEIPT


Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Please issue a corrected filing receipt for the above-referenced application. A copy of the original filing receipt with the correction to be made is marked in red ink as attached for your reference.

Respectfully submitted,

By

  
Martha Cassidy  
Attorney for Applicants  
Registration No. 44,066  
ROTHWELL, FIGG, ERNST & MANBECK, p.c.  
Suite 701-E, 555 13th Street, N.W.  
Washington, D.C. 20004  
Telephone: (202) 783-6040

1954-363.CFR

APR 20 2001

TECH CENTER 1600/2900



**UNITED STATES PATENT AND TRADEMARK OFFICE**

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/739,843	12/20/2000	1617	969	1954-363	24	23	12

**CONFIRMATION NO. 5838**

**CORRECTED FILING RECEIPT**



\*OC00000005943242\*

6449  
ROTHWELL, FIGG, ERNST & MANBECK, P.C.  
555 13TH STREET, N.W.  
SUITE 701, EAST TOWER  
WASHINGTON, DC 20004

Date Mailed: 04/06/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

**Applicant(s)**

Jerry L. Nadler, La Crescenta, CA;  
Rama Natarajan, Hacienda Heights, CA;

*Assignee: City of Hope, Duarte, CA.*  
**D** Domestic Priority data as claimed by applicant

THIS APPLICATION IS A DIV OF 08/945,744 11/03/1997 PAT 6,191,169  
WHICH IS A CIP OF PCT/US96/06328 05/03/1996  
WHICH IS A CIP OF 08/434,681 05/04/1995 ABN  
THIS APPLICATION 09739843  
IS A CIP OF PCT/US94/00089 01/04/1994  
AND A CIP OF 07/936,660 08/28/1992 ABN



**Foreign Applications**


If Required, Foreign Filing License Granted 03/05/2001

Projected Publication Date: 06/28/2001

Non-Publication Request: No

Early Publication Request: No

**\*\* SMALL ENTITY \*\***



**Title**

Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states

**Preliminary Class**

514

---

**Data entry by : BURSE, JANICE**

**Team : OIPE**

**Date: 04/06/2001**



**LICENSE FOR FOREIGN FILING UNDER**  
**Title 35, United States Code, Section 184**  
**Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

**PLEASE NOTE the following information about the Filing Receipt:**

- o The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- o The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- o The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- o The docket number allows a maximum of 25 characters.
- o If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- o The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents  
Office of Initial Patent Examination  
Customer Service Center  
Washington, DC 20231